Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1926)	10/29/2003 2:05:19 PM
From: scaram(o)uche	Respond to of 3044

>> OTOH...... << Guffaw! Well, there's the wrench. The statin disaster was thrown into the mix, after the deals were signed. Desperately needed "catch up" resources went poof.

To: nigel bates who wrote (1926)	10/29/2003 2:50:32 PM
From: A.J. Mullen	Respond to of 3044

On the third hand, if the program was so successful why abandon it? Even if you can't use all the targets, you could gain some useful IP in case someone else stumbles across them. I hoped that the targets would be regarded as capital. Or perhaps the unused targets would be like the tailings of diamond mines. They'd been worked through and the most of the biggest and best diamonds had been taken, but some had probably been missed and others could be useful little earners. DeBeers used to protect the tailings with armed guards. With Millenium and Incyte, Bayer and others are supposedly still sifting through the tailings, but are not interested in bringing anything more out of the ground. If the discovered targets are so valuable, would there be so little left undiscovered to justify abandonment of the original program? Ashley